FibroBiologics, Inc. (NASDAQ: FBLG), a clinical-stage biotechnology company, has successfully completed a public offering of approximately 2,272,728 shares of its common stock and accompanying warrants to purchase an equal number of shares. The offering, which closed on April 2, 2026, was priced at $1.32 per share, generating gross proceeds of about $3 million before deducting placement agent fees and other expenses. The company intends to utilize the net proceeds for working capital and general corporate purposes. The warrants will have an exercise price of $1.32 per share and will be exercisable following stockholder approval. H.C. Wainwright & Co. acted as the exclusive placement agent for this offering. The company has also agreed to a 30-day lock-up period post-offering, restricting the issuance of additional shares or equivalents, which is expected to help stabilize the stock price in the short term. The offering is part of FibroBiologics' strategy to enhance its financial position as it continues to develop therapeutics aimed at chronic diseases using fibroblast technology. The company holds over 270 patents and is focused on advancing its clinical pipeline. This capital raise is seen as a positive step towards strengthening its financial foundation and supporting ongoing operational activities.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.